PCI acquires Bellwyck Pharma Services

By Jenni Spinner

- Last updated on GMT

(Image: Getty/Manop1984)
(Image: Getty/Manop1984)

Related tags: Pci pharma services, Bellwyck Pharma Services, primary packaging, Secondary packaging

The purchase follows PCI’s plans to expand its clinical trial services globally, including in North America and Europe.

Headquartered in Toronto, Canada, Bellwyck focuses on primary and secondary packaging and labeling for the clinical trial and commercial drug markets. Its acquisition expands PCI Pharma Services’ network of good manufacturing practice (GMP)-compliant facilities by four.

Salim Haffar, PCI’s CEO, told Outsourcing-Pharma that the company’s recent string of acquisitions fits its goal to expand its global presence and provide greater access for customers.

Our recent acquisitions align with our purpose to be the bridge between life-changing therapies and patients around the world, helping us achieve greater access around the world for our clients.

“With the addition of Bellwyck, PCI has now established a presence in Canada and Germany, ranked third and fourth in the world for total number of clinical trials, respectively, extending the reach of PCI’s clinical services in key markets,” he said.

The clinical and commercial supply chain solutions offered by Bellwyck support PCI’s core capabilities, such as clinical trial packaging, labeling and logistics for Phase I-IV studies, and full-service commercial packaging, the company stated. The acquisition brings the number of PCI’s GMP-compliant facilities to 25 and increases its total workforce in North America, Europe and the Asia-Pacific region to more than 3,700.

The addition of Bellwyck will mark PCI’s third acquisition outside of the US in three years, demonstrating its focus on geographic expansion.

The company in August 2019 announced plans to construct a 75,000-square-foot dedicated clinical facility outside of Dublin​, Ireland. Additionally, in February 2018, the company declared its intentions to snap up Melbourne, Australia-based Pharmaceutical Packaging Professionals​.

Haffar told Outsourcing-Pharma that PCI continues to hunt for strategic acquisitions around the globe.

We are always on the lookout for partnerships that complement our capabilities and allow us to enter new markets; we will continue our strategy to ensure we are servicing our clients and the patients they serve in the best way possible,” he said.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars